Company Overview and News

Mustang Resources discovers new ruby deposit in Mozambique

Mustang Resources Ltd (ASX:MUS) has discovered a new ruby-bearing gravel deposit just 3.5 kilometres from its processing plant at the Montepuez Ruby Project in Mozambique.
Upvote Downvote

Mustang Resources makes first ruby sale from new Thailand office

Mustang Resources Ltd (ASX:MUS) has sold $230,953 worth of rubies through its newly established sales and marketing office in Thailand during March.
Upvote Downvote

Mustang Resources developing ruby and graphite-vanadium projects in Mozambique

Mustang Resources Ltd (ASX:MUS) is focused on two projects in the northern region of Mozambique in East Africa.
Upvote Downvote

Mustang Resources directors buy $128,000 worth of shares

Mustang Resources Ltd (ASX:MUS) has had two more key members of its board and management buy shares in the company.
Upvote Downvote

Mustang Resources chairman increases stake through share purchases

Mustang Resources Ltd (ASX:MUS) has received a vote of confidence from its chairman Ian Daymond who has acquired 500,000 shares.
Upvote Downvote

Mustang Resources funded and fast tracking graphite and vanadium projects

Mustang Resources (ASX:MUS) is due to release a scoping study at the end of Q2 that depicts an updated resource for graphite and a maiden resource for vanadium from its site in Mozambique, with assay and metallurgical test results set to be released in the interim. The project has been fast tracked, with managing director Dr Bernard Olivier commenting “it is a really fascinating and high-grade deposit so we are in a very unique and exceptional position.
Upvote Downvote

Mustang Resources secures $2.45 million from rights issue, multiple catalysts upcoming

Mustang Resources Ltd (ASX:MUS) has received strong shareholder support in its recently closed rights issue which has secured $2.45 million in funding.
Upvote Downvote

Mustang Resources drill result shows large potential for Caula vanadium graphite project

Mustang Resources Ltd (ASX:MUS) has drilled a hole 7.5 kilometres from previously drilled mineralisation at the Caula Graphite Vanadium project and hit high-grade graphite and vanadium.
Upvote Downvote

Mustang Resources on track for graphite and vanadium production mid-2019

Mustang Resources Ltd (ASX:MUS) has concluded from a strategic review that its Caula Graphite Vanadium Project in Mozambique could achieve first production by mid-2019.
Upvote Downvote

Mustang on track for Caula production by mid-2019

Mustang Resources could be producing at the Caula graphite-vanadium project in Mozambique by the middle of next year.
Upvote Downvote

Mustang Resources' high-grade drill results strengthen plan to develop Caula graphite-vanadium project

Mustang Resources Ltd (ASX:MUS) has released high-grade results over extensive widths from drilling at its Caula Graphite and Vanadium Project in Mozambique.
Upvote Downvote

Mustang Resources flags the potential to produce vanadium concentrate at Caula Graphite Project

Mustang Resources (ASX: MUS) has determined that the company’s Caula Graphite Project in Mozambique is well on track for first production by the middle of next year.
Upvote Downvote

Mustang adds vanadium potential to Caula strategy

Mustang Resources is on track for first production at the Caula graphite project in Mozambique by the middle of next year.
Upvote Downvote

Mustang Resources adds experienced metallurgist to board

Mustang Resources Ltd (ASX:MUS) has appointed resources industry veteran Dr Evan Kirby as a non-executive director to its board.
Upvote Downvote

Mustang Resources aligns ruby sales strategy with production, improving cashflow

Mustang Resources Ltd (ASX:MUS) has completed a review of its sales and marketing strategy, which should see the company realise revenues from its ruby inventory.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...